Braveheart Bio, Inc.
corporate_fare Company Profile
Braveheart Bio, Inc. (NASDAQ:BRVE) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 12 items for BRVE at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-10, rated 7/10. Across its 12 most recent items scored 7 or higher, the top rating is 8/10, with 5 rated 8 or above. Recent SEC coverage for BRVE spans 8-K, SCHEDULE 13D, 4.
Recent high-impact activity:
- Braveheart Posts Q3 Loss of $26.5M; $503.5M Cash Funds Runway Into 2029
- Braveheart Posts $26.5M Q3 Loss, $503.5M Cash Funds Runway Into 2029
- Braveheart's HRS/BHB-1893 Holds 52-Week Benefit; Fixed-Dose Phase 2b TRUEHEART-HCM Planned
- Braveheart's HCM Drug Holds Obstruction Gains at 52 Weeks With No Serious Events
- Braveheart Bio Reports Q2 2026 Results, Initiates Phase 3 LIONHEART-HCM Trial, Extends Cash Runway to 2029
Short Interest & Short Volume
19.63 days to coverFINRA reported short interest of 5,153,595 shares in BRVE as of the October 30, 2026 settlement, a 5.1% increase from the prior period — about 19.6 days to cover at its recent average daily volume. On November 20, 2026, 93.4% of BRVE volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for BRVE, detected from its recent SEC filings · based on capital-structure filings through 2026-08-06.
IPO Pricing Confirmed · Underwriters' Option
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →